Was appointed as a Director in February 2018, and the CEO and the Chief Scientific Officer in February 2021. He was re-designated as an executive Director in February 2021.
Dr. Li has also held positions at CARsgen Therapeutics. He has been a director and the chief executive officer since October 2014, and the chief scientific officer since December 2017.
Dr. Li has approximately 20 years of work experience in the biopharmaceutical field. Prior to joining our Group, Dr. Li was a project manager at Guilin Pavay Gene Pharmaceutical Co., Ltd. from July 2000 to April 2002. Dr. Li worked at Shanghai Cancer Institute from July 2005 to June 2018 and served as the leader of the biotherapy research team at the State Key Laboratory of Oncogenes and Related Genes of Shanghai Cancer Institute during such period.
Dr. Li has dedicated himself to developing innovative treatment for the patients with cancer. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become a widely used unnatural peptide in antitumor study now. He is also the inventor of new technologies such as Hpd3cell, a new phage display technology; FR806, a new safety switch for T cell therapy; CycloCAR technology to increase the antitumor activities of chimeric antigen receptor (CAR) T cells. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide. Dr. Li was a professor in Shanghai Cancer Institute, Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine and a doctoral supervisor at Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine.
Dr. Li obtained his bachelor’s degree in preventive medicine and master’s degree in pathology and pathophysiology from the Central South University, formerly known as the Hunan Medical University, the PRC, in June 1997 and July 2000 respectively. He obtained his Doctor of Philosophy degree in pathogen biology from Fudan University, the PRC, in June 2005.
Dr. Li was awarded the Leading Talents of Shanghai City in 2018, the Shanghai Youth Science and Technology Award, and the Shanghai May 1st Labor Medal in 2019.
Was appointed as a Director in September 2018 and the COO in February 2021. He was re-designated as an executive Director in February 2021.
Dr. Wang has also held positions at other members of our Group. He has been a director and the chief operating officer of CARsgen Therapeutics since October 2014, the general manager of CARsgen Pharmaceuticals since November 2017 and the general manager of CARsgen Diagnostics since November 2020.
Prior to joining our Group, Dr. Wang worked at Zhejiang Academy of Medical Sciences from July 2009 to January 2011, served as the deputy general manager of Shanghai Ruijin Biotechnology Co., Ltd. from January 2011 to June 2013, and the general manager of YIJIE Biotech (Shanghai) from July 2013 to October 2014.
Dr. Wang obtained his bachelor’s degree in biochemistry from Sichuan University, the PRC, in June 1999. He received his master’s degree and Doctor of Philosophy degree in pathogenic organisms from Fudan University, the PRC, in June 2003 and June 2009, respectively.
Dr. Jiang has about 18 years of working experiences in the field of cancer biotherapy. She currently serves as Vice President of Early Discovery of CARsgen, responsible for formulating the strategy of early discovery and the construction of R&D pipeline. Dr. Jiang joined the Company in April 2021 as Senior Director of Immune Cell Research and Development Department, responsible for the research work of Immune Cell Research and Development and Preclinical Pharmacology. Dr. Jiang has contributed significantly to the early research, technology platform development, and innovative products development in CARsgen. Prior to joining the Company, from July 2007 to April 2021, Dr. Jiang worked at Shanghai Cancer Institute, responsible for the research and development of antibody and CAR T cells, as well as the related mechanisms. Dr. Jiang was a professor at Shanghai Cancer Institute and a doctoral supervisor at Shanghai Jiao Tong University School of Medicine.
Dr. Jiang has published more than 20 SCI papers in journals such as Journal of the National Cancer Institute, Clinical Cancer Research, Molecular Therapy, etc. She is the first author to publish the world's first CLDN18.2 CAR T and first EGFR/EGFRvIII CAR T papers and the co-corresponding author to publish the world's first paper on the combination therapy of small molecule and CAR T cells for the treatment of solid tumors.
Dr. Jiang earned her Bachelor’s degree in Clinical Medicine from Jining Medical College in 2001. She obtained Master's degree in Pathogen Biology from Shandong University in 2004 and Ph.D. in Pathogen Biology from Fudan University in 2007.
Dr. Yi Luo joined CARsgen in 2024 as Vice President of Clinical Science, overseeing the company’s clinical sciences, medical writing, and post-marketing medical teams, and directing the strategic planning and execution of clinical science programs in China.
With experience in biopharmaceuticals, clinical development and scientific research, Dr. Luo has developed deep expertise in both hematological malignancies and solid tumors. He has successfully advanced multiple innovative drugs through different phases of clinical development (Phase I-III), as well as IND/NDA submissions and commercial launches. Prior to CARsgen, Dr. Luo served as Hematology Therapeutic Area Lead at Roche Global Pharmaceutical Development China Center, where he established and built a hematology clinical research team. In his previous roles at Kelun Pharmaceutical Research Institute and Innovent Biologics, he led clinical science teams and served as project lead for multiple programs, including regulatory submissions for CAR-T therapies and other immunotherapies. He has extensive hands-on experience in designing and implementing clinical trials for CAR-T cells bispecific antibodies, and targeted therapies.
Dr. Luo earned his PhD and MD from the Institute of Hematology of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and completed postdoctoral training at the College of Medicine, University of Arkansas. He was an attending hematologist at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, where he led translational research and clinical studies of hematological diseases, including CAR-T cell therapy, for many years.
Dr. Rajakumaraswamy brings extensive experience in clinical development and medical affairs gained from several prominent biopharmaceutical companies across the United States and Europe, along with a proven track record in team management. Prior to joining CARsgen, Dr. Rajakumaraswamy led multiple early-stage development programs in hematology/ oncology at Gilead Sciences, engaging in numerous regulatory interactions with the FDA, EMA, and other European health authorities and successfully filing several Investigational New Drug (IND) applications and Clinical Trial Authorizations (CTAs). Dr. Rajakumaraswamy has deep expertise in multiple therapeutics targets including PI3Kδ, BTK, MCL1, FLT3, CD47, CD19, BCMA, GPRC5D amongst others. He also has experience with Kite Pharma's cell therapy. Earlier in his career, Dr. Rajakumaraswamy served as a Medical Assessor at the UK's Medicines and Healthcare products Regulatory Agency (MHRA) Clinical Trials Unit, where he was the lead for cell and gene therapies. Dr. Rajakumaraswamy practiced medicine for several years within the UK's National Health Service (NHS) and earned Membership of the Royal College of Physicians (MRCP), Fellowship of the Royal College of Anaesthetists (FRCA), and Fellowship of the Faculty of Pharmaceutical Medicine (FFPM). Dr Rajakumaraswamy earned his medical degree from University College London, UK.
Dr. Zang leads CARsgen’s overall business development efforts, alliance management, and corporate strategic planning initiatives. Additionally, he oversees the strategy and management of the CARsgen's product pipeline, as well as the company’s public relations and government relations functions.
Dr. Zang joined CARsgen in 2021 from Roche, where he served as Strategic Planning Lead for Hematology and Early Assets within Roche China. He brings over a decade of professional experience across GSK, BMS, and Roche, spanning medical affairs, clinical science, marketing, portfolio and project management, and business development.
Dr. Zang holds a doctoral degree from Peking University Health Science Center and a double major Bachelor’s degree from Peking University China Center for Economics Research.